Need help now? Free crisis lines and helplines, worldwide — chapter 02 →
0 results for

Metabolic Therapies — Fasting, Formula Diets, Ketogenic Therapy, Exercise, Surgery & Medicines

Category 15 of 20 in chapter 17, The Research Behind It, of Notbroken's Free Metabolic & Mental Health Help Directory: 15 listings, each carefully picked (listed, not endorsed). All 280 listings in The Research Behind It · Open the full directory of 2299 listings.
15
Listings
15 / 20
Category
17 / 18
Chapter
Latest Edition Always download the most up-to-date version, free, at notbroken.io
Know someone who could benefit? Share this guide with them.
Free to use · No account needed
Navigation
Contents
17
The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows
THE EVIDENCE
THE EVIDENCE

The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows

Why would a support group, a walking club, a low-carb book or an online CBT course help — and what drives chronic illness in the first place? This chapter gathers the research behind each part of the directory, and the research on causes: metabolic therapies, the nutrients in food, plastics and pollution, stress and trauma, the microbiome, and damp and mould. That is 280 studies, reviews and clinical guidelines, every one free to read and download in full, permanently and without a login. Most are kept in PubMed Central, the US National Library of Medicine's public archive; the rest are open access at the publisher, or free guidance from the World Health Organization and NICE. Each entry says what was found, why it matters here — which listings it backs up, or what it explains about chronic disease — and how strong the evidence is: strong (systematic reviews and guidelines with consistent findings), moderate (smaller or lower-certainty reviews, single large trials and large cohort studies) or early (pilot, cross-sectional and laboratory studies — promising, not proof). Studies that follow people over time show links, not proof of cause, and the entries say so. Where a study was funded by a company, or its authors run a listed programme, the note says so; where a listed book or service was not itself tested, the entry says it backs the approach rather than the product. Research moves on, so read these as good reasons to try something, not guarantees — and talk to your own clinician before changing a treatment or a medicine. Every paper was checked at least twice: by the researcher who chose it and again, independently, against its abstract and full text (the first 186 a third time); its public record was checked for corrections, retractions and expressions of concern (none is retracted), every number was looked up in the full text, and every link was opened in a browser.

Metabolic Therapies — Fasting, Formula Diets, Ketogenic Therapy, Exercise, Surgery & Medicines

Effects of ketogenic diet on health outcomes: an umbrella review of meta-analyses of randomized clinical trials — Patikorn et al., BMC Med 2023

Umbrella review — 17 meta-analyses covering 68 randomised trials, re-analysed and graded with GRADE. Moderate evidence. BMC Med 2023;21:196. DOI 10.1186/s12916-023-02874-y. Free full text in PubMed Central (PMC10210275) — open access, CC BY 4.0. Note: Most trials were small and short (median 42 people, 13 weeks); whether these changes mean fewer heart attacks or longer life is unknown.
What It Found
Re-analysed and graded 17 published meta-analyses of randomised trials of ketogenic diets. High-quality evidence showed about five times as many children with drug-resistant epilepsy cutting their seizures by at least half, and, in adults with type 2 diabetes, lower triglycerides but higher LDL cholesterol. Moderate-quality evidence showed lower body weight and HbA1c. Most of the 115 effects examined rested on low or very low quality evidence.
Why It Matters Here
Backs up the ketogenic and low-carb practitioners in chapter 01, the keto communities in chapter 14 and keto books and guides in chapter 10, while showing the trade-off: weight, blood sugar and triglycerides improved, but LDL cholesterol rose by an amount the authors judged clinically meaningful.
Umbrella review — 17 meta-analyses covering 68 randomised trials, re-analysed and graded with GRADE. Moderate evidence. BMC Med 2023;21:196. DOI 10.1186/s12916-023-02874-y. Free full text in PubMed Central (PMC10210275) — open access, CC BY 4.0. Note: Most trials were small and short (median 42 people, 13 weeks); whether these changes mean fewer heart attacks or longer life is unknown.

The use of ketogenic diets in cancer patients: a systematic review — Römer et al., Clin Exp Med 2021

Systematic review — 39 studies, 770 people with cancer (3 randomised trials, 2 controlled studies, the rest single-arm studies and case reports). Early evidence. Clin Exp Med 2021;21(4):501–536. DOI 10.1007/s10238-021-00710-2. Free full text in PubMed Central (PMC8505380) — open access, CC BY 4.0. Note: Search ended in 2019; most studies were small, uncontrolled and at high risk of bias, so neither benefits nor harms are well measured.
What It Found
Gathered the clinical studies of ketogenic diets in people with cancer published up to April 2019. There was no conclusive evidence that the diet slows tumours or lengthens survival. Most patients lost a significant amount of weight and had mild to moderate side effects, and in the uncontrolled studies that measured it only 60% kept to the diet. The authors conclude that clinical evidence of benefit is still lacking.
Why It Matters Here
Explains the state of evidence on ketogenic diets for cancer, relevant to keto communities that mention cancer (Ketogenic Diet India, chapter 14) and keto practitioners in chapter 01: it is a research question, not an established cancer treatment.
Systematic review — 39 studies, 770 people with cancer (3 randomised trials, 2 controlled studies, the rest single-arm studies and case reports). Early evidence. Clin Exp Med 2021;21(4):501–536. DOI 10.1007/s10238-021-00710-2. Free full text in PubMed Central (PMC8505380) — open access, CC BY 4.0. Note: Search ended in 2019; most studies were small, uncontrolled and at high risk of bias, so neither benefits nor harms are well measured.

Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis — Karam et al., BMJ 2023

Systematic review and network meta-analysis — 40 randomised trials, 35,548 people at increased cardiovascular risk. Strong evidence. BMJ 2023;380:e072003. DOI 10.1136/bmj-2022-072003. Free full text in PubMed Central (PMC10053756) — open access, CC BY-NC 4.0. Note: Benefits rested on moderate-certainty evidence, partly from trials that also added exercise, medicines or quit-smoking help; no low-carbohydrate programme trials qualified.
What It Found
Compared named diet programmes in people at raised risk of heart disease. With moderate certainty, Mediterranean programmes reduced death from any cause (odds ratio 0.72; about 17 fewer deaths per 1,000 people at intermediate risk over five years), cardiovascular death, stroke and non-fatal heart attack compared with minimal advice. Low-fat programmes also reduced deaths and heart attacks. Ornish, Pritikin and the other programmes generally showed little or no benefit.
Why It Matters Here
Backs up the Mediterranean-style eating resources in chapter 10 (the Oldways guides): of the named diet programmes tested over the long term, Mediterranean and low-fat programmes were the ones with moderate-certainty evidence of fewer heart attacks and deaths.
Systematic review and network meta-analysis — 40 randomised trials, 35,548 people at increased cardiovascular risk. Strong evidence. BMJ 2023;380:e072003. DOI 10.1136/bmj-2022-072003. Free full text in PubMed Central (PMC10053756) — open access, CC BY-NC 4.0. Note: Benefits rested on moderate-certainty evidence, partly from trials that also added exercise, medicines or quit-smoking help; no low-carbohydrate programme trials qualified.

A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses — Esposito et al., BMJ Open 2015

Systematic review of 8 meta-analyses and 5 randomised trials, with new meta-analyses of trials lasting 6 months or more. Moderate evidence. BMJ Open 2015;5(8):e008222. DOI 10.1136/bmjopen-2015-008222. Free full text in PubMed Central (PMC4538272) — open access, CC BY-NC 4.0. Note: The diabetes-control result rests on only three trials, and the lower diabetes risk comes mainly from observational studies.
What It Found
Pulled together the evidence on Mediterranean eating in type 2 diabetes and prediabetes. In three long-term trials, a Mediterranean diet lowered HbA1c by 0.47 percentage points more than usual care or low-fat diets, and two trials found a 49% higher chance of the metabolic syndrome resolving. Earlier meta-analyses also favoured it for weight and cholesterol, and closer adherence was linked with a 19–23% lower risk of developing diabetes.
Why It Matters Here
Backs up the Mediterranean-style eating guides in chapter 10 (Oldways) as an option for people with type 2 diabetes or prediabetes, alongside low-carb approaches.
Systematic review of 8 meta-analyses and 5 randomised trials, with new meta-analyses of trials lasting 6 months or more. Moderate evidence. BMJ Open 2015;5(8):e008222. DOI 10.1136/bmjopen-2015-008222. Free full text in PubMed Central (PMC4538272) — open access, CC BY-NC 4.0. Note: The diabetes-control result rests on only three trials, and the lower diabetes risk comes mainly from observational studies.

Vegetarian and Vegan Dietary Patterns to Treat Adult Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Guest et al., Adv Nutr 2024

Systematic review and meta-analysis with GRADE ratings — 7 randomised trials, 770 adults with type 2 diabetes. Moderate evidence. Adv Nutr 2024;15(10):100294. DOI 10.1016/j.advnut.2024.100294. Free full text in PubMed Central (PMC11540868) — open access, CC BY 4.0. Note: Only seven mostly small trials lasting 12–74 weeks, with varied comparison diets; HbA1c was pooled from just five of them.
What It Found
Reviewed randomised trials of vegetarian and vegan eating for adults with type 2 diabetes. Compared with non-vegetarian diets, vegetarian diets likely lowered HbA1c by 0.40 percentage points and BMI by 0.96 (moderate-certainty evidence) and may allow less diabetes medication (low certainty). They showed no clear effect on fasting glucose, fasting insulin or LDL cholesterol.
Why It Matters Here
Backs up the plant-based cooking classes (PCRM’s Food for Life) and the plant-based meal-prep community in chapter 14: vegetarian or vegan eating is a reasonable option for type 2 diabetes, not only low-carb. Four of the seven trials were led by PCRM’s president, Neal Barnard.
Systematic review and meta-analysis with GRADE ratings — 7 randomised trials, 770 adults with type 2 diabetes. Moderate evidence. Adv Nutr 2024;15(10):100294. DOI 10.1016/j.advnut.2024.100294. Free full text in PubMed Central (PMC11540868) — open access, CC BY 4.0. Note: Only seven mostly small trials lasting 12–74 weeks, with varied comparison diets; HbA1c was pooled from just five of them.

Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial — Astbury et al., BMJ 2018

Pragmatic randomised controlled trial — 278 adults with obesity in 10 UK general practices, 1 year. Moderate evidence. BMJ 2018;362:k3760. DOI 10.1136/bmj.k3760. Free full text in PubMed Central (PMC6156558) — open access, CC BY 4.0. Note: Only 73% were re-measured at 12 months, follow-up stopped at one year, and the trial was part-funded by the formula maker.
What It Found
GP patients with obesity were randomised to a total diet replacement programme (formula foods of 810 kcal a day as the only food for 8 weeks, then food reintroduction, with weekly support) or usual practice-nurse support. At 12 months the programme group had lost 10.7 kg versus 3.1 kg (difference 7.2 kg); 45% versus 15% lost at least 10% of their weight. Mild side effects such as constipation were more common, but moderate or worse adverse events were similar (11% v 12%).
Why It Matters Here
Backs up the low-calorie, formula-first approach in Roy Taylor's Life Without Diabetes (chapter 10), showing that this kind of programme can work for people with obesity, with or without diabetes, when offered through ordinary general practice.
Pragmatic randomised controlled trial — 278 adults with obesity in 10 UK general practices, 1 year. Moderate evidence. BMJ 2018;362:k3760. DOI 10.1136/bmj.k3760. Free full text in PubMed Central (PMC6156558) — open access, CC BY 4.0. Note: Only 73% were re-measured at 12 months, follow-up stopped at one year, and the trial was part-funded by the formula maker.

Effect of Time-Restricted Eating on Weight Loss in Adults With Type 2 Diabetes: A Randomized Clinical Trial — Pavlou et al., JAMA Netw Open 2023

Randomised controlled trial — 75 adults with type 2 diabetes and obesity, 6 months. Moderate evidence. JAMA Netw Open 2023;6(10):e2339337. DOI 10.1001/jamanetworkopen.2023.39337. Free full text in PubMed Central (PMC10611992) — open access, CC BY-NC-ND 4.0. Note: Small (75 people), 6 months and not blinded; more people in the time-restricted group were already on weight-lowering diabetes drugs.
What It Found
Compared eating only between noon and 8 pm (no calorie counting), cutting calories by 25% a day, and no change. After 6 months the time-restricted group had lost 3.56% more body weight than controls; calorie cutting's 1.78% was not statistically significant, and the two diets did not differ significantly from each other. HbA1c fell by about 0.9 percentage points in both diet groups versus controls, with no serious adverse events, and low blood sugar was no more common.
Why It Matters Here
Backs up time-restricted eating, as used by the fasting communities and the Zero app in chapter 13 and the fasting books in chapter 10, as one option for people with type 2 diabetes; in the trial, glucose-lowering medicines were adjusted under a set protocol.
Randomised controlled trial — 75 adults with type 2 diabetes and obesity, 6 months. Moderate evidence. JAMA Netw Open 2023;6(10):e2339337. DOI 10.1001/jamanetworkopen.2023.39337. Free full text in PubMed Central (PMC10611992) — open access, CC BY-NC-ND 4.0. Note: Small (75 people), 6 months and not blinded; more people in the time-restricted group were already on weight-lowering diabetes drugs.

Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial — Wei et al., JAMA Netw Open 2023

Randomised controlled trial — 88 adults with obesity and fatty liver, 12 months, liver fat measured by MRI. Moderate evidence. JAMA Netw Open 2023;6(3):e233513. DOI 10.1001/jamanetworkopen.2023.3513. Free full text in PubMed Central (PMC10024204) — open access, CC BY 4.0. Note: One centre in China with young adults (average age 32); liver fat was measured by MRI, not biopsy, so effects on liver scarring are uncertain.
What It Found
Everyone followed the same calorie-reduced diet; half also ate only between 8 am and 4 pm. Liver fat (MRI) fell by 8.3 percentage points with time-restricted eating and 8.1 with calorie cutting alone at 6 months (6.9 v 7.9 at 12 months), and weight by 8.4 kg v 7.8 kg at 12 months, with no significant differences. Liver stiffness, blood pressure and blood fats improved equally; only insulin resistance improved more with time restriction, at 12 months.
Why It Matters Here
Backs up the fasting communities in chapter 13 and fasting books in chapter 10 only in part: for fatty liver, eating within an 8-hour window worked as well as ordinary calorie cutting but no better, and the authors conclude that cutting calories explains most of the benefit.
Randomised controlled trial — 88 adults with obesity and fatty liver, 12 months, liver fat measured by MRI. Moderate evidence. JAMA Netw Open 2023;6(3):e233513. DOI 10.1001/jamanetworkopen.2023.3513. Free full text in PubMed Central (PMC10024204) — open access, CC BY 4.0. Note: One centre in China with young adults (average age 32); liver fat was measured by MRI, not biopsy, so effects on liver scarring are uncertain.

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — European Association for the Study of the Liver (EASL) et al., Obes Facts 2024

Joint clinical practice guideline of the European liver, diabetes and obesity societies — graded recommendations with Delphi consensus. Strong evidence. Obes Facts 2024;17(4):374–444 (also published in J Hepatol 2024;81(3):492–542). DOI 10.1159/000539371. Free full text in PubMed Central (PMC11299976) — open access, CC BY-NC 4.0. Note: Evidence that lifestyle weight loss helps advanced scarring or cirrhosis is insufficient, and diet trials lasted only 2–24 months, so long-term liver outcomes are unknown.
What It Found
For adults with fatty liver linked to metabolic risk, recommends lasting weight loss of at least 5% to reduce liver fat, 7–10% to improve inflammation and 10% or more to improve scarring, Mediterranean-style eating with fewer ultra-processed foods and sugary drinks, and regular exercise; incretin medicines and bariatric surgery are options where indicated. Evidence was insufficient for very-low-carb ketogenic diets, and thin that time-restricted eating beats calorie cutting.
Why It Matters Here
Backs up calorie-reduced eating plans for fatty liver, Mediterranean-style (the Oldways guides, chapter 10) or lower-carb (chapters 01 and 10), and the exercise professionals in chapter 12, while flagging thin evidence for ketogenic diets and time-restricted eating.
Joint clinical practice guideline of the European liver, diabetes and obesity societies — graded recommendations with Delphi consensus. Strong evidence. Obes Facts 2024;17(4):374–444 (also published in J Hepatol 2024;81(3):492–542). DOI 10.1159/000539371. Free full text in PubMed Central (PMC11299976) — open access, CC BY-NC 4.0. Note: Evidence that lifestyle weight loss helps advanced scarring or cirrhosis is insufficient, and diet trials lasted only 2–24 months, so long-term liver outcomes are unknown.

Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia — Keating et al., Sports Med 2023

Position statement of Exercise & Sports Science Australia — evidence-graded recommendations based on systematic reviews and meta-analyses. Strong evidence. Sports Med 2023;53(12):2347–2371. DOI 10.1007/s40279-023-01918-w. Free full text in PubMed Central (PMC10687186) — open access, CC BY 4.0. Note: The fall in liver fat is modest, and there is little evidence yet that exercise alone improves liver inflammation or scarring.
What It Found
Graded the evidence for exercise in fatty liver disease. High-certainty evidence shows that regular aerobic exercise (most studies used 150–240 minutes a week of at least moderate intensity) lowers liver fat by about 2–4% in absolute terms, even without weight loss, and improves fitness. High-intensity interval training appears comparable; the effect of resistance training on liver fat is uncertain; and there is little evidence on liver inflammation or scarring.
Why It Matters Here
Backs up the accredited exercise physiologists and other clinical exercise professionals in chapter 12, and the exercise programmes in chapter 10, as part of care for fatty liver alongside diet.
Position statement of Exercise & Sports Science Australia — evidence-graded recommendations based on systematic reviews and meta-analyses. Strong evidence. Sports Med 2023;53(12):2347–2371. DOI 10.1007/s40279-023-01918-w. Free full text in PubMed Central (PMC10687186) — open access, CC BY 4.0. Note: The fall in liver fat is modest, and there is little evidence yet that exercise alone improves liver inflammation or scarring.

Effect of exercise on cardiometabolic health of adults with overweight or obesity: Focus on blood pressure, insulin resistance, and intrahepatic fat—A systematic review and meta-analysis — Battista et al., Obes Rev 2021

Systematic review and meta-analysis — 54 randomised trials in adults with overweight or obesity. Moderate evidence. Obes Rev 2021;22(Suppl 4):e13269. DOI 10.1111/obr.13269. Free full text in PubMed Central (PMC8365642) — open access, CC BY 4.0. Note: Trials were mostly small (median 38 people) and 43% were rated poor quality; results varied between studies.
What It Found
Pooled trials of exercise training programmes. Exercise lowered systolic blood pressure by about 3 mmHg and diastolic by about 2 mmHg, gave a small reduction in insulin resistance (standardised mean difference −0.34; −0.50 in people with type 2 diabetes) and a moderate reduction in liver fat measured by MRI (−0.59, 13 studies), with high-intensity interval training showing a larger effect on liver fat.
Why It Matters Here
Backs up the exercise professionals in chapter 12 and the home-workout programmes in chapter 10 as a way to improve insulin resistance, blood pressure and liver fat in people living with overweight or obesity.
Systematic review and meta-analysis — 54 randomised trials in adults with overweight or obesity. Moderate evidence. Obes Rev 2021;22(Suppl 4):e13269. DOI 10.1111/obr.13269. Free full text in PubMed Central (PMC8365642) — open access, CC BY 4.0. Note: Trials were mostly small (median 38 people) and 43% were rated poor quality; results varied between studies.

Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes — Courcoulas et al., JAMA 2024

Pooled long-term follow-up of 4 US randomised trials (ARMMS-T2D) — 262 adults with type 2 diabetes, median 11 years. Moderate evidence. JAMA 2024;331(8):654–664. DOI 10.1001/jama.2024.0318. Free full text in PubMed Central (PMC10900968). Note: Small open-label trials were pooled and 25% of the medical group later had surgery; a 2026 Cochrane review rated long-term remission evidence very uncertain.
What It Found
Adults with type 2 diabetes and obesity had been randomised to bariatric surgery (gastric bypass, sleeve or band) or medical and lifestyle care. At 7 years HbA1c had fallen by 1.6 percentage points after surgery versus 0.2 with medical care; diabetes remission was 18.2% v 6.2% at 7 years and 12.7% v 0% at 12 years, with fewer diabetes medicines. Anaemia, fractures and gut problems were more common after surgery.
Why It Matters Here
Explains the long-term benefits and trade-offs of metabolic surgery for type 2 diabetes, useful context for readers comparing it with the diet-based remission approaches described in chapter 10.
Pooled long-term follow-up of 4 US randomised trials (ARMMS-T2D) — 262 adults with type 2 diabetes, median 11 years. Moderate evidence. JAMA 2024;331(8):654–664. DOI 10.1001/jama.2024.0318. Free full text in PubMed Central (PMC10900968). Note: Small open-label trials were pooled and 25% of the medical group later had surgery; a 2026 Cochrane review rated long-term remission evidence very uncertain.

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis — Nong et al., BMJ 2026

Systematic review and network meta-analysis — 262 randomised trials, 99,791 adults, 19 drugs, GRADE. Strong evidence. BMJ 2026;394:e372161. Free full text at the publisher — open access, CC BY-NC 4.0. Note: Follow-up ranged from 12 to 172 weeks, so long-term benefits and harms, especially of the newest drugs, remain uncertain.
What It Found
At one year, compared with lifestyle change alone, tirzepatide gave the most extra weight loss (14.9%), then cagrilintide-semaglutide (14.8%), oral semaglutide (10.9%), orforglipron (9.9%) and injected semaglutide (9.8%) (moderate to high certainty). Larger losses generally came with more side effects and stopping. Only injected semaglutide reduced deaths and heart attacks (mostly in trials of high-risk people), and no drug meaningfully improved quality of life.
Why It Matters Here
Explains what modern weight-loss medicines can and cannot do, so readers can weigh them against the diet, fasting and exercise approaches in this directory (chapters 01, 10, 12 and 13) with their clinician.
Systematic review and network meta-analysis — 262 randomised trials, 99,791 adults, 19 drugs, GRADE. Strong evidence. BMJ 2026;394:e372161. Free full text at the publisher — open access, CC BY-NC 4.0. Note: Follow-up ranged from 12 to 172 weeks, so long-term benefits and harms, especially of the newest drugs, remain uncertain.

Weight regain after cessation of medication for weight management: systematic review and meta-analysis — West et al., BMJ 2026

Systematic review and meta-analysis — 37 studies (63 treatment arms), 9,341 adults with overweight or obesity. Moderate evidence. BMJ 2026;392:e085304. DOI 10.1136/bmj-2025-085304. Free full text in PubMed Central (PMC12776922) — open access, CC BY 4.0. Note: Only one study followed people for two years after stopping; for the newest drugs, regain beyond 12 months was projected rather than observed.
What It Found
After stopping weight-loss medicines, people regained on average 0.4 kg a month, with weight projected to return to its starting point about 1.7 years later and gains in blood sugar, cholesterol and blood pressure projected to reverse within about 1.4 years. Regain was faster after the newer incretin drugs (0.8 kg a month) and faster than after behavioural weight-loss programmes, whatever the initial weight loss.
Why It Matters Here
Explains that the benefits of weight-loss medicines fade quickly once they stop, faster than after behavioural programmes: useful context for readers weighing medicines against, or alongside, the lifestyle resources in chapters 10, 12, 13 and 14.
Systematic review and meta-analysis — 37 studies (63 treatment arms), 9,341 adults with overweight or obesity. Moderate evidence. BMJ 2026;392:e085304. DOI 10.1136/bmj-2025-085304. Free full text in PubMed Central (PMC12776922) — open access, CC BY 4.0. Note: Only one study followed people for two years after stopping; for the newest drugs, regain beyond 12 months was projected rather than observed.

Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation — Valabhji et al., Lancet Diabetes Endocrinol 2024

National prospective service evaluation — 7,540 people referred in England; 1,740 started the 12-month programme in time to be assessed. Moderate evidence. Lancet Diabetes Endocrinol 2024;12(9):653–663. Free full text at the publisher — open access, CC BY. Note: An uncontrolled service evaluation: only 55% completed the programme and many lacked HbA1c results, so the true remission rate is uncertain and lower than in the trials.
What It Found
The NHS offered adults aged 18–65 diagnosed with type 2 diabetes in the last 6 years a 12-month programme starting with 12 weeks of total diet replacement (soups and shakes, about 800–900 kcal a day) plus coaching. Among 1,710 starters with weight data, mean weight loss at a year was 9.4 kg (10.3 kg among completers). Of those with two HbA1c results recorded, 27% were in remission (32% of completers).
Why It Matters Here
Backs up the diet-led remission approach in Professor Roy Taylor's book Life Without Diabetes in chapter 10 (he is a co-author) and shows the approach can work in an ordinary health service, not only in trials.
National prospective service evaluation — 7,540 people referred in England; 1,740 started the 12-month programme in time to be assessed. Moderate evidence. Lancet Diabetes Endocrinol 2024;12(9):653–663. Free full text at the publisher — open access, CC BY. Note: An uncontrolled service evaluation: only 55% completed the programme and many lacked HbA1c results, so the true remission rate is uncertain and lower than in the trials.
Important Disclaimer
This directory is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your medication regimen or starting any new therapy.

This document does not guarantee the legitimacy, quality, or suitability of any business, organization, or practitioner listed within. The inclusion of any listing does not constitute an endorsement, recommendation, or verification of credentials. All organizations listed are independent entities over which the creators of this directory have no control or oversight.

This directory is intended to be used as a starting point and reference for the reader to conduct their own research, exercise their own judgment, and apply their own discretion before engaging with any listed organization or professional. Readers are strongly encouraged to independently verify credentials, read reviews, check licensing, and confirm current pricing and availability directly with each organization before committing to any services.

Costs, availability, contact details, and services may change at any time without notice. Information was accurate to the best of our knowledge at the time of publication.

About Notbroken.io: this directory and the accompanying Breathe, Calm, Sleep, Move, Eat, Track and Build tools were created by Nathan Leary, who runs and updates them. How each tool works, its safety notes, the privacy policy and terms of use are at notbroken.io/about, notbroken.io/privacy and notbroken.io/terms. The tools are general wellness aids, not medical devices, and Track is a personal journal that never gives medication advice.

If you are in crisis: Please contact your local emergency services immediately, or reach out to one of the following helplines:

International: Chapter 02 of this directory lists free helplines by situation and country; elsewhere use Find A Helpline — findahelpline.com
United States: 988 Suicide & Crisis Lifeline (call or text 988) • Crisis Text Line (text HOME to 741741)
United Kingdom: Samaritans — 116 123 (free, 24/7)
Canada: Talk Suicide Canada — 988 (call or text, 24/7)
Australia: Lifeline — 13 11 14 (24/7) • Beyond Blue — 1300 22 4636
New Zealand: Need to Talk? — 1737 (free, 24/7)
Europe: European Emergency Number — 112
India: iCall — 9152987821 • Vandrevala Foundation — 1860 2662 345
Singapore: Samaritans of Singapore — 1-767 (24/7)
Japan: TELL Lifeline — 03-5774-0992

No matches found

Nothing matched . Try broadening your search — remove a filter, use a single keyword, describe what you need in a sentence, or browse by a condition, a place, or a type of support.

Suggest a resource